3 stories found
Samsung Biologics has published a prospectus for a public tender offer to acquire Danish biotechnology company PolyPeptide Group, with the formal takeover bid expected to launch in September. The move expands Samsung's capabilities in peptide synthesis and contract manufacturing services.
Samsung Biologics intends to raise approximately 3 trillion won through a rights offering to finance its proposed acquisition of peptide maker PolyPeptide Group. The capital injection will support the company’s broader expansion strategy in the contract development and manufacturing sector.
Samsung Biologics has announced its acquisition of Swiss peptide manufacturer PolyPeptide Group in an all-cash deal valued at $1.81 billion. This strategic move expands Samsung Biologics' presence into the peptide market.